Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;25(11):1691-705.e4.
doi: 10.1016/j.jvir.2014.08.027. Epub 2014 Oct 23.

Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update

Muneeb Ahmed  1 , Luigi Solbiati  2 , Christopher L Brace  3 , David J Breen  4 , Matthew R Callstrom  5 , J William Charboneau  5 , Min-Hua Chen  6 , Byung Ihn Choi  7 , Thierry de Baère  8 , Gerald D Dodd 3rd  9 , Damian E Dupuy  10 , Debra A Gervais  11 , David Gianfelice  12 , Alice R Gillams  13 , Fred T Lee Jr  14 , Edward Leen  15 , Riccardo Lencioni  16 , Peter J Littrup  17 , Tito Livraghi  18 , David S Lu  19 , John P McGahan  20 , Maria Franca Meloni  21 , Boris Nikolic  22 , Philippe L Pereira  23 , Ping Liang  24 , Hyunchul Rhim  25 , Steven C Rose  26 , Riad Salem  27 , Constantinos T Sofocleous  28 , Stephen B Solomon  28 , Michael C Soulen  29 , Masatoshi Tanaka  30 , Thomas J Vogl  31 , Bradford J Wood  32 , S Nahum Goldberg  33 ; International Working Group on Image-Guided Tumor Ablation; Interventional Oncology Sans Frontières Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe
Affiliations

Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update

Muneeb Ahmed et al. J Vasc Interv Radiol. 2014 Nov.

Abstract

Image-guided tumor ablation has become a well-established hallmark of local cancer therapy. The breadth of options available in this growing field increases the need for standardization of terminology and reporting criteria to facilitate effective communication of ideas and appropriate comparison among treatments that use different technologies, such as chemical (eg, ethanol or acetic acid) ablation, thermal therapies (eg, radiofrequency, laser, microwave, focused ultrasound, and cryoablation) and newer ablative modalities such as irreversible electroporation. This updated consensus document provides a framework that will facilitate the clearest communication among investigators regarding ablative technologies. An appropriate vehicle is proposed for reporting the various aspects of image-guided ablation therapy including classification of therapies, procedure terms, descriptors of imaging guidance, and terminology for imaging and pathologic findings. Methods are addressed for standardizing reporting of technique, follow-up, complications, and clinical results. As noted in the original document from 2003, adherence to the recommendations will improve the precision of communications in this field, leading to more accurate comparison of technologies and results, and ultimately to improved patient outcomes.

PubMed Disclaimer

Conflict of interest statement

M.A. No relevant conflicts of interest to disclose. L.S. No relevant conflicts of interest to disclose. C.L.B. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received consultancy fees from NeuWave Medical, author and institution received payment for patents (planned, pending, or issued) from University of Wisconsin and NeuWave Medical, received payment for stock/stock options from NeuWave Medical. Other relationships: none to disclose. D.J.B. Financial activities related to the present article: paid for occasional proctoring by Galil Medical. Financial activities not related to the present article: none to disclose. Other relationships: none to disclose. M.R.C. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received grants from Galil Medical, Siemens Medical, GE Medical, Thermedical. Other relationships: none to disclose. J.W.C. No relevant conflicts of interest to disclose. M.H.C. No relevant conflicts of interest to disclose. B.I.C. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: institution received a research grant from Samsung Electronics. Other relationships: none to disclose. T.d.B. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received personal fees from Terumo, a grant from HS-Medical, and payment for travel to a meeting from Boston-Scientific. Other relationships: none to disclose. G.D.D. No relevant conflicts of interest to disclose. D.E.D. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: paid for board membership by BSD Medical, received consultancy fees from BSD Medical and Covidien, received grants or has grants pending from NeuWave Medical, received payment for lectures including service on speakers bureaus from BSD Medical, was paid royalties by Springer Verlag and UpToDate, received stock or stock options from BSD Medical. Other relationships: none to disclose. D.A.G. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received a research grant from Covidien/Valleylab. Other relationships: none to disclose. D.G. No relevant conflicts of interest to disclose. A.R.G. Financial activities related to the present article: received consulting fee or honorarium from Covidien, received fees for participatient in review activities such as data monitoring boards, statistical analysis, end point committees, and the like from Covidien. Financial activities not related to the present article: was paid for board membership, consultancy, and lectures including service on speakers bureaus by Covidien. Other relationships: none to disclose. F.T.L. Financial activities related to the present article: received payment from NeuWave Medical. Financial activities not related to the present article: received royalties from Covidien, is a stockholder and on the Board of Directors for NeuWave Medical, has a patent on the Switching Controller with royalties paid from Covidien, has multiple patents on heat-based thermal therapies for microwave ablation systems licensed to NeuWave Medical. Other relationships: none to disclose. E.L. No relevant conflicts of interest to disclose. R.L. No relevant conflicts of interest to disclose. P.J.L. No relevant conflicts of interest to disclose. T.L. No relevant conflicts of interest to disclose. D.S.L. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: institution received grants or has grants pending from Endocare and Ethicon Endo-Surgery, received payment for lectures including service on speakers bureaus from Philips. Other relationships: none to disclose. J.P.M. No relevant conflicts of interest to disclose. M.F.M. No relevant conflicts of interest to disclose. B.N. No relevant conflicts of interest to disclose. P.L.P. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received a grant from Celon Olympus; fees for conferences from Siemens Medical Solutions; consultant’s honoraries from Terumo Europe, Terumo Germany, and Microsulis; materials from AngioDynamics. Other relationships: none to disclose. P.L. No relevant conflicts of interest to disclose. H.R. No relevant conflicts of interest to disclose. S.C.R. No relevant conflicts of interest to disclose. R.S. No relevant conflicts of interest to disclose. C.T.S. No relevant conflicts of interest to disclose. S.B.S. Financial activities related to the present article: institution received a grant from GE Healthcare; author received consulting fee or honorarium from AngioDyamics, Covidien, and GE Healthcare. Financial activities not related to the present article: none to disclose. Other relationships: none to disclose. M.C.S. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: author received consultancy fees from Guerbet LLC, BTG, Merit Medical; institution received grants or has grants pending from Guerbet LLC and BTG; author received payment for lectures including service on speakers bureaus from Sirtex; author received royalties from Cambridge University Press. Other relationships: none to disclose. M.T. No relevant conflicts of interest to disclose. T.J.V. No relevant conflicts of interest to disclose. B.J.W. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: institution received grants or has grants pending from Cooperative Research and Development Agreement (CRADA) Philips Healthcare, CRADA Biocompatibles BTG, CRADA Perfint, CRADA Celsion, CRADA Invivo; the National Institutes of Health has intellectual property in the field. Other relationships: none to disclose. S.N.G. Financial activities related to the present article: institution received a grant for sponsored research from AngioDynamics; author received consulting fee or honorarium from AngioDynamics. Financial activities not related to the present article: author received consultancy fees from Cosman Medical and institution received grants or has grants pending from Cosman Medical. Other relationships: none to disclose.

References

ADDITIONAL CLINICAL STUDIES: LONG-TERM STUDIES AND RANDOMIZED, CONTROLLED STUDIES

    1. Ambrogi MC, Fanucchi O, Cioni R, et al. Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study. J Thorac Oncol 2011; 6:2044–2051. - PubMed
    1. Francica G, Saviano A, De Sio I, et al. Long-term effectiveness of radiofrequency ablation for solitary small hepatocellular carcinoma: a retrospective analysis of 363 patients. Dig Liver Dis 2013; 45:336–341. - PubMed
    1. Gillams AR, Lees WR. Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. J Vasc Interv Radiol 2008; 19:712–717. - PubMed
    1. Ma Y, Bedir S, Cadeddu JA, Gahan JC. Long-term outcomes in healthy adults following radiofrequency ablation of T1a renal tumours. BJU Int 2014; 113:51–55. - PubMed
    1. Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 2007; 243:268–275. - PubMed

ADDITIONAL SOCIETY POSITION STATEMENTS ON TUMOR ABLATION

    1. Brown DB, Gould JE, Gervais DA, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009; 20:S425–S434. - PubMed
    1. Callstrom MR, York JD, Gaba RC, et al. Research reporting standards for image-guided ablation of bone and soft tissue tumors. J Vasc Interv Radiol 2009; 20:1527–1540. - PubMed
    1. Clark TW, Millward SF, Gervais DA, et al. Reporting standards for percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol 2009; 20:S409–S416. - PubMed
    1. Rose SC, Dupuy DE, Gervais DA, et al. Research reporting standards for percutaneous thermal ablation of lung neoplasms. J Vasc Interv Radiol 2009; 20:S474–S485. - PubMed

DIFFERENT METHODS OF TUMOR ABLATION

    1. Ward RC, Healey TT, Dupuy DE. Microwave ablation devices for interventional oncology. Expert Rev Med Devices 2013; 10:225–238. - PubMed
    1. Cheung W, Kavnoudias H, Roberts S, Szkandera B, Kemp W, Thomson KR. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat 2013; 12:233–241. - PubMed
    1. Cressman EN, Shenoi MM, Edelman TL, et al. In vivo comparison of simultaneous versus sequential injection technique for thermochemical ablation in a porcine model. Int J Hyperthermia 2012; 28:105–112. - PubMed
    1. Shiina S, Tagawa K, Niwa Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol 1993; 160:1023–1028. - PubMed
    1. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54:1151–1156. - PMC - PubMed

REPORTING APPLICATOR, DEVICE, AND ENERGY APPLICATION/ALGORITHIM PARAMETERS

    1. Meijerink MR, van den Tol P, van Tilborg AA, van Waesberghe JH, Meijer S, van Kuijk C. Radiofrequency ablation of large size liver tumours using novel plan-parallel expandable bipolar electrodes: initial clinical experience. Eur J Radiol 2011; 77:167–171. - PubMed
    1. Aguilar-Garib JA. Medical applications: the ISM band. J Microw Power Electromagn Energy 2010; 44:131. - PubMed
    1. Brace CL. Dual-slot antennas for microwave tissue heating: parametric design analysis and experimental validation. Med Phys 2011; 38:4232–4240. - PMC - PubMed
    1. Koda M, Tokunaga S, Matono T, Sugihara T, Nagahara T, Murawaki Y. Comparison between different thickness umbrella-shaped expandable radiofrequency electrodes (SuperSlim and CoAccess): experimental and clinical study. Exp Ther Med 2011; 2:1215–1220. - PMC - PubMed
    1. Miao Y, Ni Y, Yu J, Zhang H, Baert A, Marchal G. An ex vivo study on radiofrequency tissue ablation: increased lesion size by using an “expandable-wet” electrode. Eur Radiol 2001; 11:1841–1847. - PubMed

TISSUE PROPERTIES AFFECTING ABLATION

    1. Ahmed M, Liu Z, Humphries S, Goldberg SN. Computer modeling of the combined effects of perfusion, electrical conductivity, and thermal conductivity on tissue heating patterns in radiofrequency tumor ablation. Int J Hyperthermia 2008; 24:577–588. - PubMed
    1. Ahmed M, Liu Z, Afzal KS, et al. Radiofrequency ablation: effect of surrounding tissue composition on coagulation necrosis in a canine tumor model. Radiology 2004; 230:761–767. - PubMed
    1. Yu NC, Raman SS, Kim YJ, Lassman C, Chang X, Lu DS. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. J Vasc Interv Radiol 2008; 19:1087–1092. - PubMed
    1. Chang I, Mikityansky I, Wray-Cahen D, Pritchard WF, Karanian JW, Wood BJ. Effects of perfusion on radiofrequency ablation in swine kidneys. Radiology 2004; 231:500–505. - PMC - PubMed
    1. Kim C, O’Rourke AP, Will JA, Mahvi DM, Webster JG. Finite-element analysis of hepatic cryoablation around a large blood vessel. IEEE Trans Biomed Eng 2008; 55:2087–2093. - PubMed

CONCOMITANT, COMBINATION, AND CONCURRENT THERAPIES

    1. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26:985–990. - PubMed
    1. Merkle EM, Goldberg SN, Boll DT, et al. Effects of superparamagnetic iron oxide on radio-frequency-induced temperature distribution: in vitro measurements in polyacrylamide phantoms and in vivo results in a rabbit liver model. Radiology 1999; 212:459–466. - PubMed
    1. Hakimé A, Hines-Peralta A, Peddi H, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology 2007; 244:464–470. - PubMed
    1. Ahmed M, Liu Z, Lukyanov AN, et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 2005; 235:469–477. - PubMed
    1. Wood BJ, Poon RT, Locklin JK, et al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol 2012; 23:248–255, e7. - PMC - PubMed

IMAGE GUIDANCE IN ABLATION

    1. Jolesz FA, Silverman SG. Interventional magnetic resonance therapy. Semin Intervent Radiol 1995; 12:20–27.
    1. Kurup AN, Morris JM, Schmit GD, et al. Neuroanatomic considerations in percutaneous tumor ablation. RadioGraphics 2013; 33:1195–1215. - PubMed
    1. Ryan ER, Sofocleous CT, Schöder H, et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology 2013; 268:288–295. - PMC - PubMed
    1. Gazelle GS, Haaga JR. Guided percutaneous biopsy of intraabdominal lesions. AJR Am J Roentgenol 1989; 153:929–935. - PubMed
    1. Lewin JS, Connell CF, Duerk JL, et al. Interactive MRI-guided radiofrequency interstitial thermal ablation of abdominal tumors: clinical trial for evaluation of safety and feasibility. J Magn Reson Imaging 1998; 8:40–47. - PubMed

ANCILLARY PROCEDURES

    1. Chen MH, Yang W, Yan K, et al. Radiofrequency ablation of problematically located hepatocellular carcinoma: tailored approach. Abdom Imaging 2008; 33:428–436. - PubMed
    1. Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma. II. Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol 2005; 185:72–80. - PubMed
    1. Lee SJ, Choyke LT, Locklin JK, Wood BJ. Use of hydrodissection to prevent nerve and muscular damage during radiofrequency ablation of kidney tumors. J Vasc Interv Radiol 2006; 17:1967–1969. - PMC - PubMed
    1. Kam AW, Littrup PJ, Walther MM, Hvizda J, Wood BJ. Thermal protection during percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol 2004; 15:753–758. - PMC - PubMed
    1. Uehara T, Hirooka M, Ishida K, et al. Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites. J Gastroenterol 2007; 42:306–311. - PubMed

PATHOLOGY AND IMAGING

    1. Sofocleous CT, Garg S, Petrovic LM, et al. Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol 2012; 19:4262–4269. - PMC - PubMed
    1. Snoeren N, Huiskens J, Rijken AM, et al. Viable tumor tissue adherent to needle applicators after local ablation: a risk factor for local tumor progression. Ann Surg Oncol 2011; 18:3702–3710. - PMC - PubMed
    1. Fujisawa S, Romin Y, Barlas A, et al. Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases. Cytotechnology 2014; 66:259–273. - PMC - PubMed
    1. Zervas NT, Kuwayama A. Pathological characteristics of experimental thermal lesions. Comparison of induction heating and radiofrequency electrocoagulation. J Neurosurg 1972; 37:418–422. - PubMed
    1. Wu F, Wang ZB, Cao YD, et al. Heat fixation of cancer cells ablated with high-intensity-focused ultrasound in patients with breast cancer. Am J Surg 2006; 192:179–184. - PubMed

REPORTING COMPLICATIONS AND SIDE EFFECTS

    1. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology 2003; 226:441–451. - PubMed
    1. Rhim H, Yoon KH, Lee JM, et al. Major complications after radiofrequency thermal ablation of hepatic tumors: spectrum of imaging findings. RadioGraphics 2003; 23:123–134; discussion 134–136. - PubMed
    1. Vogl TJ, Straub R, Eichler K, Woitaschek D, Mack MG. Malignant liver tumors treated with MR imaging–guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002; 225:367–377. - PubMed
    1. Dodd GD 3rd, Napier D, Schoolfield JD, Hubbard L. Percutaneous radiofrequency ablation of hepatic tumors: postablation syndrome. AJR Am J Roentgenol 2005; 185:51–57. - PubMed
    1. Narayanan G, Froud T, Lo K, Barbery KJ, Perez-Rojas E, Yrizarry J. Pain analysis in patients with hepatocellular carcinoma: irreversible electroporation versus radiofrequency ablation-initial observations. Cardiovasc Intervent Radiol 2013; 36:176–182. - PubMed

FOLLOW-UP AND OUTCOMES

    1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–216. - PubMed
    1. Li H, Guo Z, Si T, Wang H. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation. Eur J Gastroenterol Hepatol 2013; 25:620–627. - PubMed
    1. Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? a validation study of old and new models. Radiology 2012; 262:708–718. - PubMed
    1. Fong Y, Blumgart LH, Cohen AM. Surgical treatment of colorectal metastases to the liver. CA Cancer J Clin 1995; 45:50–62. - PubMed
    1. Molmenti EP, Marsh JW, Dvorchik I, Oliver JH 3rd, Madariaga J, Iwatsuki S. Hepatobiliary malignancies: primary hepatic malignant neoplasms. Surg Clin North Am 1999; 79:43–57, viii. - PubMed

References

    1. Goldberg SN, Charboneau JW, Dodd GD III, et al. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology 2003; 228:335–345. - PubMed
    1. Froeling V, Meckelburg K, Schreiter NF, et al. Outcome of uterine artery embolization versus MR-guided high-intensity focused ultrasound treatment for uterine fibroids: long-term results. Eur J Radiol 2013; 82:2265–2269. - PubMed
    1. Groeschl RT, Pilgrim CH, Hanna EM, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2014; 259:1195–1200. - PubMed
    1. Narayanan G, Hosein PJ, Arora G, et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012; 23:1613–1621. - PubMed
    1. Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 2013; 58:89–97. - PubMed

Publication types